How much funding has BridgeBio raised?

BridgeBio has raised $1.7B in total funding, most recently a Growth Equity round.

Who are BridgeBio's investors?

BridgeBio's investors include Blue Owl Capital, KKR, Viking Global, Canada Pension Plan Investment Board, Qatar Investment Authority, HCRx.

Where is BridgeBio headquartered?

BridgeBio is headquartered in San Francisco Bay Area, California, United States.

What industry is BridgeBio in?

BridgeBio operates in Biotech, Life Sciences, Healthcare, pharmaceuticals.

How many employees does BridgeBio have?

BridgeBio has 201-500 employees.

BridgeBio

formerly BridgeBio PharmaIPO

We exist to bring meaningful medicines to patients quickly & safely.

Public · San Francisco Bay Area, United States · Founded 2014 · $1.7B raised

Headquarters: San Francisco Bay Area, California
Employees: 201–500
Founded: 2014
Business Model: Other
Website: bridgebio.com

Total Funding: $1.7B
Last Round: $500.0M Growth EquityJan 2024
Rounds: 5
Type: Public

About

BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. It has a late-stage investigational pipeline including Acoramidis for ATTRv, BBP-418 for LGMD2I/R9, Encaleret for ADH1 and hypoparathyroidism, Infigratinib for achondroplasia and hypochondroplasia, and BBP-812 for Canavan Disease.

Summary

BridgeBio is a Biotech company based in San Francisco Bay Area, United States, founded in 2014. It has raised $1.7B in total across 5 rounds, most recently a $500.0M Growth Equity round in Jan 2024. Investors include Blue Owl Capital, KKR and Viking Global.

LinkedIn X (Twitter)